Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The study set out to analyse the dose-response relationship of semaglutide in T2D and obesity, testing doses up to eight times higher than the currently approved maximum
Venkatakrishnan AJ et al
Daraxonrasib is showing major OS improvements in pancreatic cancer after KRAS was considered undruggable for decades Pharma is no longer just about selling drugs its becoming an ecosystem of data, diagnostics, AI, prevention and highly personalized care
Perets R, Geva R, McKean M, et al
US$ 26.90
US$ 23.47
US$ 27.16
US$ 26.81
US$ 23.63
US$ 26.82
